Enhancing Allergy Diagnostics Starting With the Lab

Food allergies affect as many as 250 million people worldwide, yet they remain under-recognized in primary care. Food allergens can cause a wide variety of symptoms, and some cross-react with others, making accurate diagnosis difficult. Patients often self-diagnose and eliminate foods from their diet, but without proper testing, that approach can be misleading and rarely produces the best path forward.

The complexity of food allergy testing is precisely why the laboratory plays such a central role in supporting accurate diagnosis and clinical decision-making. Laboratory testing gives clinicians objective data to work from and helps move care beyond symptom-based assumptions.

Laboratory results, however, should not be the final decision maker. Clinical judgment and patient history remain essential to interpreting what those results mean for treatment.

Primary care providers (PCPs) are often the first point of contact for patients with suspected food allergies, so evaluation needs to follow a structured, guideline-based approach. Laboratories support clinicians in this work by improving confidence in diagnostic decisions and helping guide the next steps in care.

The evolving role of the laboratory in allergy diagnosis

Laboratory testing is central to distinguishing between sensitization and true clinical allergy. Standard testing can identify whether a patient is sensitized to a specific allergen, but sensitization alone does not confirm clinical reactivity. Results must be interpreted within the full clinical context.

Modern laboratory infrastructure, including standardized assays and improved analytical methods, supports more consistent and sensitive detection of allergen-specific immunoglobulin E (IgE).

This allows clinicians to evaluate potential triggers more accurately, assess the likelihood of clinical allergy, and decide when further evaluation, such as an oral food challenge, is appropriate.

Test results should always be interpreted alongside patient history. A positive result without clinical symptoms does not necessarily confirm a food allergy, while a negative result reduces the likelihood of IgE-mediated allergy, particularly when assessed using a high-quality serum-specific IgE assay.

These relationships are not always clear-cut and should not be interpreted in isolation.

The growing role of component-resolved diagnostics

One of the most meaningful shifts in allergy diagnostics is the increasing use of component-resolved diagnostics (CRD), which builds on traditional whole allergen testing to give clinicians a more precise understanding of allergic sensitization and risk at the molecular level.

CRD adds a layer of granularity, without replacing established methods, that improves how clinicians interpret results along with patient history.

Whole allergen testing remains an important tool. It helps identify potential allergic triggers and confirms sensitization to allergen sources such as peanuts, eggs, or tree nuts.

What it cannot do is distinguish which specific proteins within an allergen are responsible for immune activation, which limits its ability to differentiate sensitization from clinically relevant allergy.

CRD addresses that limitation by identifying sensitization to individual allergenic proteins within a source. This protein-level resolution allows clinicians to recognize risk patterns that are not visible through whole allergen testing alone.

In peanut allergy, sensitization to storage proteins such as Ara h 1, Ara h 2, Ara h 3, and Ara h 6 is more strongly associated with systemic and clinically significant reactions.

Sensitization to Ara h 8, by contrast, may reflect cross-reactivity with pollens and is often associated with either no clinical symptoms or milder oral symptoms consistent with pollen food allergy syndrome (PFAS).

Similar principles apply across other food allergens, where specific protein targets help clarify whether a sensitization is likely to be clinically meaningful.

Cell and Gene Therapies: The Evolution of Advanced Biologics

This eBook takes a look at the challenges shaping advanced biologics, alongside practical strategies to improve consistency, scalability, and compliance across development and manufacturing.

View eBook

Advertisement

This added specificity matters in the context of evolving prevention strategies. As evidence continues to support early peanut introduction in infancy to reduce allergy risk, clinicians rely more heavily on laboratory data to help determine which infants may safely proceed with early exposure and which need further evaluation.

In these scenarios, combining whole allergen testing with CRD improves diagnostic specificity, reduces unnecessary dietary restrictions, and helps clinicians avoid higher-risk oral food challenges when they are not clinically indicated.

By moving toward a layered diagnostic model that incorporates both whole allergen and component-level information, clinicians are better equipped to distinguish sensitization from true clinical allergy and to tailor more precise recommendations for prevention, diagnosis, and management.

Interpreting results in clinical context

Testing is only one part of the diagnostic process and should be used to clarify, not complicate, patient care. Choosing the right test matters: studies have indicated that of the 35% of patients who self-report a food allergy, only 3.5% will have a confirmed clinical allergy. Over-testing without context risks adding confusion where clarity is what the patient needs.

Laboratories support accurate detection by running standardized, highly sensitive assays. That level of sensitivity and specificity allows clinicians to distinguish clinical allergies from sensitization, guide oral food challenges safely, and make evidence-based recommendations about early potentially allergenic food introduction or avoidance.

Lab professionals play an essential role in assisting primary care clinicians with early detection, initial testing for allergen triggers, guideline-recommended management, and referral to specialists when appropriate.

Clinical reactivity thresholds vary across allergens and across individuals and need to be interpreted in that context. The higher the level of specific IgE antibodies, the higher the risk for symptomatic allergy.

Liquid Biopsies in Cancer: Technologies, Applications, and Emerging Advances

This infographic provides an overview of liquid biopsy workflows, applications, and innovations addressing current limitations.

View Infographic

Advertisement

A positive test result without clinical symptoms does not confirm an allergy. Clinicians need to interpret the result in combination with the patient's history.

A negative result makes food allergy considerably less likely, especially when measured with a highly sensitive assay such as a specific IgE test, which can detect even low IgE levels. If symptoms persist despite a negative test, the culprit allergen may have been missed.

Strengthening the lab–clinician partnership

PCPs need to feel confident ordering the right test for the right patient. This is where the lab can guide primary care and streamline ordering before a specialist referral is needed.

Modern laboratory infrastructure, including integrated workflows and digital decision-support tools, further strengthens this partnership by enabling lab professionals to deliver faster, more contextually rich results. That helps PCPs move from a test result to clinical action more efficiently.

Reassessing the patient's history and possible exposures is where a test result translates into a clinical decision. This is what helps PCPs move past the “wait and see” approach and act on the lab data once it has been interpreted. An extra layer of detail can make a real difference for patients living with food allergies.

A strong relationship between the lab and PCPs strengthens clinical judgment and decision support on both sides. Access to high-quality specific IgE assays helps clinicians navigate symptom thresholds with confidence and better understand what their patients are actually allergic to.

Toward precision-driven allergy care

Food allergies remain a significant and under-recognized clinical challenge, which makes the case for more precise, context-driven diagnostic approaches. CRD is a meaningful advance, allowing clinicians to move from broad sensitization testing toward more detailed, protein-level risk assessment.

The full value of these advances depends on integrating laboratory data with clinical context and supporting that integration with structured interpretive tools. By combining precision diagnostics with stronger clinical support, laboratories can play a central role in improving diagnostic accuracy and enabling more personalized, evidence-based allergy care.

Accurate diagnosis also cuts down on unnecessary dietary restrictions, which supports greater diet diversity and better nutritional outcomes for patients.